The activation of an inducible caspase (iCaspase-9) mediates apoptosis of neovascular endothelial cells, and overcomes the prosurvival effect of vascular endothelial growth factor or basic fibroblast growth factor. The potential utilization of direct activation of caspases as an antiangiogenic strategy for treatment of angiogenesis-dependent diseases (eg cancer) requires expression of the inducible caspase primarily in the tumor endothelium. The objective of this work was to develop and characterize a transcriptionally targeted adenoviral vector that mediates expression of iCaspase-9 specifically in neovascular endothelial cells. We observed that adenoviral vectors containing the human VEGFR2 promoter induced reporter gene expression primarily in proliferating human dermal microvascular endothelial cells (HDMEC). HDMEC transduced with recombinant adenoviral vectors containing iCaspase-9 under regulation of the VEGFR2 promoter (Ad-hVEGFR2-iCaspase-9) and exposed to a cell-permeable dimerizer drug (AP20187), presented higher caspase-3 activity and apoptosis than controls (Pp0.05). Using the SCID Mouse Model of Human Angiogenesis, we observed that local delivery of AdhVEGFR2-iCaspase-9 followed by intraperitoneal injection of AP20187 resulted in endothelial cell apoptosis and local ablation of microvessels. We believe that this constitutes the first report of a transcriptionally targeted antiangiogenic adenoviral vector that mediates neovascular disruption upon activation of a caspase-based artificial death switch. Gene Therapy (2005) 12, 320-329.
Introduction
Angiogenesis is a requirement for the growth of solid tumors. 1 However, it is becoming increasingly evident that each tumor cell uses a distinct combination of proangiogenic factors to acquire and maintain their own microvascular network. [2] [3] [4] Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are two of the most predominant proangiogenic factors in tumors, and have been shown to function as strong inducers of endothelial cell survival. [5] [6] [7] [8] We have recently demonstrated that the direct activation of caspase-9 induces apoptosis of proliferating endothelial cells, that the endothelial cell survival factors VEGF and bFGF do not protect these cells against apoptosis, and that activated iCaspase-9 is sufficient to disrupt blood vessels in vivo. 9 These experiments established proof-of-principle data to support the concept that direct activation of a proapoptotic caspase in endothelial cells might be beneficial for the treatment of solid tumors. 9 However, the utilization of a caspase-based artificial death switch as an antiangiogenic therapeutic strategy would require that the therapeutic gene be expressed only in neovascular endothelial cells, and not expressed in mature blood vessels. Recombinant adenoviruses have been used for gene therapy because of their stability and infection efficiency in vivo, and relative low risk for secondary mutagenesis. 10, 11 Several strategies have been developed to enhance the safety of adenovirus-mediated gene therapy. First, one can design vectors that incorporate cell-or tissue-specific promoters and enhancers to limit expression of the therapeutic gene. 12, 13 Second, a targeted adenoviral vector can be developed by removing its interaction with native receptors and introducing a cell-or tissue-specific ligand to the virus. 14 The use of transcriptional and/or receptor-targeting strategies may allow for the use of lower viral titers, and perhaps reduce the chance for an acute immune response. And third, the use of a suicide gene such as an inducible caspase (iCaspase) may be considered a 'safety switch' for gene therapy since the infected cells will be induced to undergo apoptosis. [15] [16] [17] Tissue specificity of an adenoviral vector to neovascular endothelial cells might be increased by the utilization of the promoter and/or enhancer of vascular endothelial growth factor receptor 2 (VEGFR2), also called KDR or Flk-1. VEGFR2 is poorly expressed in mature blood vessels, however, its expression is upregulated in the proliferating endothelium of several tumors. [18] [19] [20] It has been reported that a 939-bp mouse VEGFR2 promoter fragment and a 430-bp mouse enhancer fragment mediated strong endothelium-specific reporter gene expression in mammary adenocarcinomas grown in transgenic mice, while reporter gene expression was absent from most blood vessels in normal tissues. 20 Furthermore, a 494 bp fragment (À226 to +268) of the human VEGFR2 promoter was shown to be capable of driving expression primarily in endothelial cells following retroviral delivery. 21 , 22 Here, we tested both the human and the mouse VEGFR2 transcriptional elements to identify which one mediates stronger and more specific expression of reporter genes transduced with an adenoviral vector into neovascular endothelial cells.
'Artificial death switches' based on chemically induced dimerization (CID) of caspases with lipid-permeable and nontoxic dimerizer drugs have been described. 13, 17, 23, 24 In this approach, a protein can be fused to a CID-binding domain that will mediate noncovalent crosslinking by high-affinity interactions with a dimerizer compound. 15 When the catalytic domain of caspase-9 is fused to one or more CID-binding domains, the resulting fusion protein (inducible caspase-9, named iCaspase-9) can be activated with a dimerizer compound (eg AP20187) and initiate an irreversible signaling pathway that results in cell death. 9, 13, 17, 24 In a previous report, we have characterized a stable endothelial cell line expressing iCaspase-9, and demonstrated that activation of this caspase-based artificial death switch was sufficient to induce apoptosis. 9 Here, we used a transcriptional targeting strategy to generate an adenoviral vector containing the human VEGFR2 promoter and showed that it drives expression of reporter genes primarily in neovascular endothelial cells. We showed that activation of adenovirally delivered iCaspase-9 with the dimerizer compound AP20187 activated endogenous caspase-3 and induced endothelial cell apoptosis in vitro. Furthermore, we showed that activation of iCaspase-9 with AP20187 was sufficient to induce apoptosis of neovascular endothelial cells, and to cause a marked decrease in tissue microvessel density in vivo. Here, we combined two of the three strategies described above (ie transcriptional targeting of the vector and use of an artificial death switch) to develop a novel adenovirus-mediated antiangiogenic strategy, and demonstrated its efficacy in vivo.
Results
Adenoviruses containing the human VEGFR2 promoter mediated expression of reporter genes primarily in proliferating endothelial cells
We decided to target transcriptionally our adenoviral vectors with the regulatory elements of VEGFR2, because this receptor is expressed primarily in proliferating endothelial cells. 20, 25 We first compared the intensity of reporter gene expression under the regulation of either human or mouse VEGFR2 transcriptional elements ( Figure 1a ) after transient transfection of the constructs into proliferating human dermal microvascular endothelial cells (HDMEC). We observed that the human VEGFR2 promoter construct allowed for higher reporter gene expression levels in proliferating HDMEC, as Figure 1 Human VEGFR2 promoter mediates preferential reporter gene expression in human endothelial cells. (a) Schematic diagram depicting the luciferase reporter constructs used in this study. (b) Luciferase gene expression mediated by human VEGFR2 promoter, mouse VEGFR2 promoter, or mouse VEGFR2 promoter and mouse VEGFR2 enhancer in HDMECs. Constructs were transiently transfected into HDMECs with Lipofectin, and luciferase activity was evaluated after 24-72 h. (c) The specificity of expression mediated by human VEGFR2 promoter in primary human endothelial cells was evaluated by transfecting the pGL2-hVEGFR2 promoter-Luc into HDMEC, human dermal fibroblasts (HDF), mouse embryonic fibroblasts (MEF), NIH3T3, two oral squamous cell carcinoma cell lines (UM-SCC-17B and OSCC-3), and a breast carcinoma cell line (SK-BR-3) with Lipofectin. Data is expressed as fold induction of expression mediated by pGL2-hVEGFR2 promoter-Luc overexpression mediated by pGL2-Basic (promoter-less control), from triplicate samples per condition. HDMEC transfected with pGL2-Control (SV40 promoter and enhancer driving luciferase expression) were the positive controls.
Caspase-mediated antiangiogenic gene therapy W Song et al compared with either mouse VEGFR2 promoter alone or mouse VEGFR2 promoter and enhancer together ( Figure  1b) . To further evaluate the tissue specificity of this transcriptional element, we tested the ability of the human VEGFR2 promoter to drive specific expression in proliferating HDMEC by transfecting the reporter constructs into a panel of cell lines. We observed that the activity of the human VEGFR2 promoter is 98-fold higher than a promoter-less control plasmid (ie pGL2-Basic) in HDMEC, and comparable with the activity observed with the nonspecific SV40 promoter from the pGL2-Control plasmid (Figure 1c) . In contrast, the activity of the human VEGFR2 promoter was minimal in all other cell lines evaluated, including 1.6-fold induction (human dermal fibroblasts), 1.6-fold induction (mouse embryonic fibroblasts), 7.0-fold induction (breast cancer cell line, SK-BR-3), and 2.3-and 3.8-fold induction (squamous cell carcinoma cell lines, UM-SCC17B and OSCC-3, respectively) (Figure 1c) . Taken together, these data demonstrated that the human VEGFR2 promoter was able to drive strong and specific expression in proliferating HDMEC in vitro, and suggested that this promoter might be the basis of a viable strategy to build transcriptionally targeted antiangiogenic adenoviral vectors.
Therefore, we designed and characterized three recombinant adenoviruses to evaluate the expression patterns of a reporter gene (ie LacZ) in proliferating endothelial cells (Figure 2a) . We observed that the human VEGFR2 promoter mediated relatively strong LacZ expression in HDMEC, which was comparable to the expression observed when the nonspecific CMV promoter was used (Figure 2b ). Importantly, VEGFR2-driven expression retained specificity to neovascular endothelial cells, while CMV was clearly nonspecific (Figure 3) . Further, we observed that the human VEGFR2 promoter-driven expression of LacZ was relatively long lasting and significantly higher than baseline even 14 days after infection in vitro (Figure 2c ).
To confirm that the recombinant adenoviruses constructed with human VEGFR2 promoter retained a similar cell-type specificity of reporter gene expression that we obtained with our transient transfection experiments, we transduced HDMEC, human dermal fibroblasts, and two human squamous cell carcinoma cell lines (ie UM-SCC-17B and OSCC-3) and evaluated LacZ expression in vitro and in vivo. With recombinant AdhVEGFR2-LacZ adenoviruses, we observed staining of proliferating HDMEC but not staining of the remaining cell types evaluated here (Figure 3) . In contrast, all cell lines expressed LacZ when the CMV promoter was used ( Figure 3) .
To evaluate if adenovirally transduced endothelial cells retained their ability to differentiate into mature and functional human blood vessels in mice, we transduced HDMEC in vitro with Ad-hVEGFR2-LacZ (or promoterless, Ad-LacZ) 48 h prior to transplantation, seeded the cells in biodegradable scaffolds, and implanted them subcutaneously in immunodeficient mice using the SCID Mouse Model of Human Angiogenesis.
9,26 At 14 days after implantation, we observed that the blood vessels inside the scaffolds were positive for b-galactosidase (b-gal), which demonstrates that they were lined with the human endothelial cells that we implanted, and that adenoviral transduction of the cells did not block their ability to differentiate into blood vessels in vivo ( Figure   4a -c). Interestingly, the endothelial cells lining functional blood vessels inside the scaffold stained positive for b-gal, but the blood vessels in the fascia surrounding the implants were not stained ( Figure 4b ). These findings demonstrated that the staining is specific to transduced endothelial cells. Transduction of the endothelial cells with promoter-less (Ad-LacZ) adenoviral vector did not induce detectable staining of tissue sections ( Figure 4d ).
To further evaluate the practical applicability of this system under more physiological conditions, we performed experiments in which we first implanted untransduced HDMEC into the scaffolds, waited for 14 days, and then injected the adenoviruses locally to Caspase-mediated antiangiogenic gene therapy W Song et al evaluate the specificity of human VEGFR2 promoterdriven expression in vivo. We observed that AdhVEGFR2-LacZ allowed for endothelial cell-specific expression under the experimental conditions described here, since only the cells lining blood vessels were stained positively for b-gal ( Figure 4e ). Delivery of promoter-less control adenoviruses did not allow for observable staining of the tissue sections ( Figure 4f ). These data demonstrated that the human VEGFR2 promoter was effective in inducing endothelial cellspecific expression in vivo, and served as the basis for the development of the transcriptionally targeted adenoviral vectors for endothelial cell-specific delivery of iCaspase-9 described below.
Expression and dimerization-induced processing of adenovirally transduced iCaspase-9 in proliferating endothelial cells
To begin the characterization of the recombinant adenoviruses that expressed iCaspase-9 under the human VEGFR2 promoter, we performed a dose-response experiment and observed that increasing the multiplicity of infection ( 
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In a time course experiment, we observed that 48 h after infection, the expression of iCaspase-9 reached its maximum level and remained at a similar expression level for at least 96 h in vitro (Figure 5b) . Notably, in the absence of dimerizer drug, there was minimal detectable processing of iCaspase-9 (not shown).
To determine if adenovirally transduced iCaspase-9 is processed upon chemically induced dimerization, we treated HDMEC infected with 20 or 200 M.O.I. AdiCaspase-9 (promoter-less) or Ad-hVEGFR2-iCaspase-9 with the dimerizer drug AP20187. 27 We observed that the chimeric iCaspase-9 is processed in an AP20187-dependent manner (Figure 5c ), while no significant changes were observed in the expression levels of endogenous caspase-9 ( Figure 5c ). To confirm the specificity of iCaspase-9 expression mediated by Ad-hVEGFR2-iCaspase-9, we infected HDMEC, NIH3T3, and UM-SCC-17B. We observed that only HDMEC expressed iCaspase-9, and that it was consistently processed upon exposure of the cells to AP20187 (Figure 5d ).
Activation of adenovirally transduced iCaspase-9 induces apoptosis and caspase-3 activity in proliferating endothelial cells To evaluate if AP20187-induced processing of iCaspase-9 resulted in the induction of endothelial cell apoptosis, we exposed HDMEC to Ad-hVEGFR2-iCaspase-9 or control viruses, and treated the cells with the dimerizer drug AP20187. Thereafter, we observed a significant increase in the percentage of apoptotic endothelial cells exposed to Ad-hVEGFR2-iCaspase-9 and treated with AP20187, but not in the absence of the dimerizer drug (Figure 6e ). To study if the activation of iCaspase-9 transduced into HDMEC is capable of activating the endogenous proapoptotic signaling pathway, we exposed HDMEC to Ad-hVEGFR2-iCaspase-9 or control adenoviruses and measured caspase-3 activity. We observed that HDMEC exposed to the virus and treated with AP20187 presented an increase in caspase-3 activity, which was not observed when no promoter adenoviral controls were transduced or when the cells were not exposed to AP20187 (Figure 6f ). These data demonstrated that exposure of endothelial cells transduced with Ad-hVEGFR2-iCaspase-9 to AP20187 is sufficient to initiate a caspase-3-dependent signaling pathway that results in endothelial cell apoptosis in vitro.
Ad-hVEGFR2-iCaspase-9 induces endothelial cell apoptosis and is antiangiogenic through an AP20187-dependent process in vivo
To evaluate if adenovirally transduced iCaspase-9 is effective in decreasing tissue microvascular density in vivo, we implanted untransduced HDMEC into SCID mice as described, 9,26 allowed them to differentiate into functional blood vessels for 14 days, 26 and then delivered Ad-hVEGFR2-iCaspase-9 by a single intraimplant injection of the virus. Starting 2 days after delivery of adenoviruses, mice were injected with AP20187 or PBS intraperitonealy for 3 consecutive days. We observed that microvessel density was decreased significantly (Po 0.05?) in AP20187-treated mice that were infected with Ad-hKDR-iCaspase-9 (Figure 7e , f, and i), but not in control mice (Figure 7a-d, and i) . To confirm that the Local delivery of Ad-hVEGFR2-iCaspase-9 induces endothelial cell apoptosis and is antiangiogenic through an AP20187-dependent process in vivo. (a-h) Representative photomicrographs of implants in which 5 Â 10 10 Ad-hVEGFR2-iCaspase-9 or Ad-iCaspase-9 viral particles were delivered in vivo by local injection. (a-f) Factor VIII immunostaining to study the effects mediated by Ad-hVEGFR2-iCaspase-9 or Ad-iCaspase-9 on the local microvasculature. (a-c) Representative fields of mice injected daily for 3 days with control PBS, or (d-h) with 2 mg/kg AP20187. These implants were retrieved from mice that received three daily intraperitoneal injections of AP20187. (g, h) TUNEL staining of implants that were injected with AdiCaspase-9 or Ad-hVEGFR2-iCaspase-9. Black arrows point to TUNEL-positive endothelial cells lining the walls of microvessels. Photomicrographs are at Â 400 magnification, except for panels (c) and (f) that are at Â 100 magnification. (i) Graph depicting the average number of microvessels (7s.d.) per high power field ( Â 200) in implants in which 5 Â 10 10 Ad-hVEGFR2-iCaspase-9 or Ad-iCaspase-9 viral particles were delivered in vivo by local injection, retrieved from mice that received three daily intraperitoneal injections of PBS or 2 mg/kg AP20187. Microvessel density data were calculated from 12 implants per group, from five randomly selected microscopic fields per implant.
Caspase-mediated antiangiogenic gene therapy W Song et al decrease in microvessel density was caused by endothelial cell apoptosis, we performed in situ TUNEL assays. We observed the appearance of TUNEL-positive endothelial cells in mice exposed to Ad-hVEGFR2-iCaspase-9 and treated with AP21087 (Figure 7h ), but not in when Ad-iCaspase-9 was delivered to the implants (Figure 7g) . Thus, Ad-hVEGFR2-iCaspase-9 induces apoptosis of endothelial cells and disruption of microvessels in vivo upon conditional induction of caspase-9 activity with a dimerizer drug.
Discussion
Deregulated angiogenesis is an integral component of the pathobiology of cancer. 1, 28 The microvascular network might be a promising target for cancer gene therapy because: (A) neovascular endothelial cells are strategically accessible to the gene therapy vectors delivered through the blood stream; and (B) it is estimated that each microvascular endothelial cell supports up to 100 tumor cells. 29 The primary objective of antiangiogenic strategies proposed for the treatment of cancer is to eliminate pathologic microvessel networks while sparing the remaining vasculature. Recent advances in the design of vectors for gene therapy combined with the development of tightly regulated 'artificial death switches' led to the novel antiangiogenic gene therapy strategy presented here. We developed and characterized a recombinant adenoviral vector capable of mediating expression of iCaspase-9 primarily in neovascular endothelial cells, and demonstrated that activation of this chimeric protein is sufficient to disrupt angiogenic blood vessels in vivo.
Transcriptional targeting of adenoviral vectors is a strategy that has been used extensively to direct expression of therapeutic genes to their target cell population, and to improve safety. 12, 13 Several neovascular endothelial cell-specific markers have been characterized, such as VEGFR2, Tie, and VE-Cadherin. [30] [31] [32] [33] For this study, we selected VEGFR2 for transcriptionally targeting our viral vectors because this receptor is not expressed in most vascular endothelial cells from adult organisms but it is strongly and specifically upregulated in tumor microvessel networks. 20, 30, 34 Here, we compared the ability of the human VEGFR2 promoter, 21, 22 and the murine VEGFR2 promoter/enhancer 20 to drive expression of our recombinant adenoviruses primarily in proliferating neovascular human endothelial cells. We observed that both the human and the murine VEGFR2 transcription regulatory sequences drove expression specifically in proliferating endothelial cells, which is in agreement with previous reports. However, the human VEGFR2 promoter mediated highest expression levels in proliferating HDMEC, when compared to the murine transcriptional elements tested here. The recombinant adenoviral vectors constructed with the human VEGFR2 promoter retained the specificity of expression in HDMEC in vitro and in angiogenic microvessels in vivo, which is consistent with our initial observations in experiments involving the transfection of luciferasebased plasmids. These findings suggest that the use of the VEGFR2 promoter might allow for enhancing the safety of a gene therapy-based antiangiogenic strategy by limiting expression of the therapeutic gene to the target cells, that is, the endothelial cells of proliferating microvessels.
Others have shown that inducible proapoptotic caspases might be incorporated into gene therapy approaches for cancer. 13, 24 We decided to use an inducible system for our proposed antiangiogenic gene therapy strategy for the following reasons: (A) It allows for control of the effects of the therapeutic gene. The therapeutic gene is only activated when the dimerizer drug is delivered to the recipient of the adenoviruses. Therefore, if a potential deleterious effect is identified after delivery of the adenoviruses, the therapy can still be halted simply by not delivering the activating (dimerizer) drug. And, (B) Cells that are transduced with the adenovirus will undergo apoptosis upon exposure to the dimerizer drug. Therefore, the risk of viral-induced cell transformation is minimized by the fact that the transduced cells will be eliminated by apoptosis.
We observed a dose-dependent increase in iCaspase-9 expression with adenoviral titers of up to 200 M.O.I., and a tightly regulated processing of the iCaspase-9 protein upon its activation with the cell-permeable dimerizer drug AP20187. This processing resulted in an increase in the percentage of apoptotic cells that was observed specifically in endothelial cells treated with AP20187, but not in other cell types (data not shown) exposed to the same drug. Neither did we observe apoptosis when promoter-less adenoviral vectors were used in the same cells. Interestingly, cells that were transduced with AdhVEGFR2-iCaspase-9 and exposed to AP20187 presented a significant increase in the activity of endogenous caspase-3. These data confirmed the ability of transduced iCaspase-9 to activate the endogenous proapoptotic signaling pathway upon dimerization with AP20187 in neovascular endothelial cells.
Interestingly, approximately 44% of the endothelial cells infected with Ad-hVEGFR2-iCaspase-9 and exposed to AP20187 undergo apoptosis. This was somewhat lower than we expected initially, because we had observed before that approximately 90% of the endothelial cells stably expressing iCaspase-9 undergo apoptosis upon exposure to AP20187, 9 and that about 90% of the endothelial cells were positive for b-gal when AdhVEGFR2-LacZ was used here. These puzzling findings were perhaps clarified when we performed immunostaining in endothelial cells infected with Ad-hVEGFR2-iCaspase-9 and observed that only about 48% of the cells actually expressed iCaspase-9. Our interpretation of these results is that a subset of cells transduced at the highest level underwent apoptosis in a CID-independent fashion and that most of the remaining cells that express iCaspase-9 become apoptotic when exposed to AP20187, implying that the expression of the reporter gene (in this case LacZ) may not be directly correlated with the expression of the therapeutic gene (ie iCaspase-9).
Nevertheless, we observed a dramatic decrease in microvessel density in the implants treated with AdhVEGFR2-iCaspase-9 and injected with AP20187, which was in contrast with the microvessel density observed upon the delivery of promoter-less adenoviruses or control injections. This was correlated with the presence of apoptotic (ie TUNEL-positive) endothelial cells in microvessels from implants treated with Ad-hVEGFR2-iCaspase-9 and AP20187. In contrast, no TUNEL staining was observed when implants were injected with Caspase-mediated antiangiogenic gene therapy W Song et al promoter-less adenoviruses (ie Ad-iCaspase-9) in mice treated with AP20187, or when implants injected with Ad-hVEGFR2-iCaspase-9 in mice treated with PBS. These findings correlate well with emerging evidence that suggest that microvascular disruption does not require that every single endothelial cell undergo apoptosis. It is speculated that hemorrhage and blood flow perturbations caused by the apoptosis of some endothelial cells lining the walls of the microvessels may be enough to induce signaling cascades that result in the disruption of the vascular network. In summary, we describe here the development and characterization of a novel recombinant adenoviral vector designed for the treatment of pathologies that are characterized by aberrant angiogenesis. We demonstrated its specificity of infection in proliferating endothelial cells and also its efficacy in inducing endothelial cell apoptosis and eliminating blood vessels in vivo. We believe that the recombinant adenoviral vector presented here can be used to induce selective and regulated disruption of angiogenic neovascular networks, and therefore we are currently testing its safety and efficacy for treatment of solid tumors. This vector could become a powerful new tool for antiangiogenic gene therapy of cancer.
Materials and methods

VEGFR2 promoter/enhancer cloning and sequencing
A 494 bp human VEGFR2 promoter fragment containing sequence from À226 to +268 was amplified by PCR from human genomic DNA. 21, 22 The sequences of PCR primers were 5 0 -TACAGGTTAACAAAGTTGTTGCT CTGGGATGTTCTC-3 0 and 5 0 -AATGAAGCTTGGGAG CCGGTTCTTTCTCCCAGCGC-3 0 . A 957 bp mouse VEGFR2 (Flk-1) promoter fragment containing sequence from +1 to +939 was amplified by PCR from mouse genomic DNA. 20 The sequences of PCR primers were 5 0 -TACCGACCCAGCCAGGAAGTTC-3 0 and 5 0 -GT GCCCAGCGCGAGGTGCAGG-3 0 . A 447 bp mouse VEGFR2 enhancer fragment containing the minimal sequence from +1 to +430 was amplified by PCR from mouse genomic DNA. 20 The sequences of PCR primers were 5 0 -TACAGGTTAACAAAGTTGTTGCTCTGGGA TGTTCTC-3 0 and 5 0 -AATGAAGCTTGGGAGCCGGTT CTTTCTCCCAGCGC-3 0 . The PCR conditions were set to denature at 951C for 1 min, then 941C for 30 s, 681C for 3 min, total 30 cycles, followed by extension at 681C for 3 min. The PCR products of human VEGFR2 promoter, mouse VEGFR2 promoter and enhancer were subcloned into pGEM-T Easy vector (Promega, Madison, WI, USA), and sequenced to confirm absence of mutations.
Luciferase assays
The hVEGFR2 promoter fragment was released from pGEM-T vector by digestion with HpaI and HindIII, and was then inserted into pGL2-Basic (Promega) to generate pGL2-hVEGFR2-luc. The mouse VEGFR2 promoter fragment was released from pGEM-T vector by digestion with KpnI and HindIII, and was then inserted into pGL2-Basic to generate pGL2-mVEGFR2-luc. The mouse VEGFR2 enhancer fragment was released from pGEM-T vector by digestion with BamH1 and SalI, and was then inserted into pGL2-mVEGFR2-luc to generate pGL2-mVEGFR2-promoter/enhancer-luc. Transient transfections were carried out with 1.0 mg of the appropriate reporter construct along with 20 ng of pRL-TK (Rluc, encoding Renilla luciferase, Promega) with Lipofectin (Invitrogen Corp., Carlsbad, CA, USA). Cell extracts were prepared 24 h after transfection with lysis buffer (Promega). Luciferase activity was measured with the Dual Luciferase Reporter Assay System (Promega) in a luminometer (Turner Designs Instrument, Sunnyvale, CA, USA). The ratio of luciferase activity to Renilla luciferase activity in each sample served as a measure of normalized luciferase activity. The normalized luciferase activity was divided by that of pGL2-Basic and expressed as relative luciferase activity. Data for each construct were presented as the mean of triplicate wells, and was reproducible in three independent experiments.
Generation of adenoviruses
Adenoviral shuttle plasmids were constructed with the backbone of pACpL+loxP-SSP or pACCMVpLpA(-)loxP-SSP (University of Michigan Vector Core). The LacZ fragment was released from pCMV-SPORT-Bgal (Invitrogen) by digestion with EcoRI and BamHI. It was then inserted into the shuttle plasmids to generate pAC-lacZ (no promoter) and pAC-CMV-lacZ. The iCaspase-9 fragment was released from pSH1-iCaspase-9 13 by digestion with NotI and EcoRI. It was then inserted into pACpL+loxP-SSP to generate pAC-iCaspase-9 (no promoter). The hVEGFR2 promoter fragment was released from pGEM-T vector by digestion with HpaI and HindIII. It was then inserted into pAC-lacZ or pAC-iCaspase-9 to generate pAC-hVEGFR2-lacZ and pAC-hVEGFR2-iCasp9. The University of Michigan Vector Core generated Ad-hVEGFR2-lacZ, Ad-iCaspase-9, Ad-hVEGFR2-iCaspase-9, and we generated Ad-LacZ and Ad-CMVLacZ adenoviruses using the Cre-loxP system. 
Western blotting
HDMEC were infected with Ad-iCaspase-9 or AdhVEGFR2-iCaspase-9 at 0-200 M.O.I. After 48 h, cells were treated with 0-100 nM AP20187 (Ariad Pharmaceuticals, Cambridge, MA, USA). After a 96-h exposure to AP20187, protein lysates were prepared with lysis buffer (10 mM Tris-Cl (pH 8.0), 140 mM NaCl, 0.1% SDS, 1% NP-40). Cell debris was removed by centrifugation, and supernatants were boiled in 1:1 sample buffer (50 mM Tris-Cl (pH 6.8), 2% SDS, 10% glycerol, 0.01% bromophenol blue, 100 mM DTT). Proteins were separated on 10% SDS-PAGE gels, membranes were probed with monoclonal mouse anti-caspase-9 antibody (Oncogene, Caspase-mediated antiangiogenic gene therapy W Song et al San Diego, CA, USA), or monoclonal mouse anti-HA antibody (Babco, Berkeley, CA, USA) followed by exposure to appropriate peroxidase-coupled secondary antibodies and exposure to ECL (Amersham, Piscataway, NJ, USA). Blots were reprobed with monoclonal mouse anti-GAPDH antibody (Chemicon, Temecula, CA, USA) to control for equal loading.
CytoSpins and HA immunostaining HDMEC were infected with Ad-iCaspase-9 or AdhVEGFR2-iCaspase-9 at 0-200 M.O.I. After 48 h, cells were harvested and 10 5 cells were centrifuged against a histological slide and immediately fixed in methanol for 15 min at room temperature. Cells were incubated with 3% H 2 O 2 for 5 min at room temperature, blocked and incubated with anti-HA antibody (Babco) at 1:100 dilution for 1 h at 371C. Then slides were incubated with biotinylated secondary antibody for 20 min, streptavidin-HRP for 15 min, and with AEC substrate for 7 min. Slides were counterstained with hematoxylin for 3 s.
Flow cytometry
HDMEC and UM-SCC-17B were infected with AdiCaspase-9 or Ad-hVEGFR2-iCaspase-9 at 0-200 M.O.I. After 24 h, cells were exposed to 0-100 nM AP20187 for 0-96 h. Cells were harvested, washed, stained with 40 mg/ml Annexin V (BD Biosciences Clontech, Palo Alto, CA, USA), and evaluated by flow cytometry as described. 9 Fluorometric assay of caspase-3 activity HDMEC were seeded in six-well plates 18 h before infection. Cells were infected with Ad-iCaspase-9 or AdhKDR-iCaspase-9 at 20 or 200 M.O.I. for 24 h. Cells were treated with 0 or 100 nM AP20187 for additional 96 h. Both attached and floating cells were retrieved and lysed in the lysis buffer (50 nM HEPES, 1 mM DTT, 0.1 mM EDTA and 0.1% CHAPS (pH 7.4)). Cell extracts were resuspended in the assay buffer (100 mM NaCl, 50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% glycerol, 0.1% CHAPS). The reactions were carried out at 371C in presence of 10 mM Ac-DEDV-AMC (Alexis Biochemicals, San Diego, CA, USA). The fluorometric activity was monitored in a Spectrofluoroluminometer (TECAN) at excitation wavelength of 360 nm and emission 465 nm for up to 180 min. Recombinant human caspase-3 (Alexis) was used as positive control. Data were obtained from triplicate wells per cell and condition from three independent experiments.
SCID mouse model of human angiogenesis
Functional human microvessels were induced in severe combined immunodeficient (SCID) mice (CB-17 SCID; Taconic, Germantown, NY, USA), as described. 9, 26 Briefly, 1 Â 10 6 HDMEC were seeded in poly-(L-lactic acid) (PLLA, Medisorb, Cincinnati, OH, USA) biodegradable scaffolds, and two scaffolds were implanted subcutaneously into the dorsum of each SCID mouse. HDMEC were infected with Ad-LacZ, Ad-hVEGFR2-lacZ, AdiCaspase-9, or Ad-hVEGFR2-iCaspase-9 at 200 M.O.I. for 48 h before they were harvested and seeded in the scaffolds. Alternatively, scaffolds containing untransduced HDMEC were implanted in the mice, and 5 Â 10 10 particles/scaffold Ad-LacZ, Ad-hVEGFR2-lacZ, Ad-iCaspase-9, or Ad-hVEGFR2-iCaspase-9 were injected locally 10 days after implantation. All mice were euthanized 14 days after implantation. Prior to euthanasia, the animals received a daily intraperitoneal injection of 2 mg/kg AP20187 (Ariad) in a solution of 10% PEG 400 and 1.7% Tween 20 for 3 consecutive days. The implants were retrieved and fixed in 10% neutralbuffered formalin for 30 min at 41C, and processed for b-gal staining or for histology. The care and treatment of mice were in accordance with University of Michigan's institutional guidelines.
b-Gal staining for paraffin-embedded tissue sections Immediately after retrieval, implants removed from the SCID mice were immersed in washing buffer (0.1 M NaPO 3 (pH 8.3), 2 mM MgCl 2 , 0.1% sodium deoxycholate, 0.02% Triton X-100) and stained overnight in the dark with the staining solution (1 mg/ml X-gal, 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6-3H 2 O) at 41C. Next day, implants were rinsed thoroughly in H 2 O, then fixed in 10% neutral-buffered formalin for additional 1 h, and processed for histology. After deparafinization, the slides were stained with 0.1% safranin O for 3 min, rinsed briefly in H 2 O, dehydrated in 95% followed by 100% ethanol for 30 s each, and cleared in xylene for 30 s before mounting.
Immunolocalization of microvessels and in situ TUNEL assay
Microvessels were identified by incubating tissue sections with polyclonal rabbit anti-human Factor VIII antibody (Lab Vision Corp., Freemont, CA, USA). 26, 35 The number of stained microvessels was counted in five randomly selected fields per implant at Â 200, from 12 implants per condition. TUNEL staining (ApopTag peroxidase in situ apoptosis detection kit; Chemicon) was used according to the manufacturer's instructions. 7, 9, 35 Statistical analysis Statistical significance was determined at the Pp0.05 level, using one-way ANOVA and the Student-Newman-Keuls test.
